BOLT Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -1330.06% compared to Bolt Biotherapeutics's net margin of --. Bolt Biotherapeutics's return on equity of -64.69% beat Nanoviricides's return on equity of --.

Bolt Biotherapeutics has a consensus price target of $1.13, signalling upside risk potential of 204.05%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 360.99%. Given that Nanoviricides has higher upside potential than Bolt Biotherapeutics, analysts believe Nanoviricides is more attractive than Bolt Biotherapeutics.

Bolt Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

Bolt Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Bolt Biotherapeutics quarterly revenues are $1.1M, which are larger than Nanoviricides quarterly revenues of --. Bolt Biotherapeutics's net income of -$15.9M is lower than Nanoviricides's net income of -$2M. Notably, Bolt Biotherapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics is 1.44x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -1330.06% compared to Bolt Biotherapeutics's net margin of --. Bolt Biotherapeutics's return on equity of -64.69% beat Oragenics's return on equity of --.

Bolt Biotherapeutics has a consensus price target of $1.13, signalling upside risk potential of 204.05%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 455.56%. Given that Oragenics has higher upside potential than Bolt Biotherapeutics, analysts believe Oragenics is more attractive than Bolt Biotherapeutics.

Bolt Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Bolt Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Bolt Biotherapeutics quarterly revenues are $1.1M, which are larger than Oragenics quarterly revenues of --. Bolt Biotherapeutics's net income of -$15.9M is lower than Oragenics's net income of -$3.3M. Notably, Bolt Biotherapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics is 1.44x versus 1.12x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Internet Patents Corporation has a net margin of -1330.06% compared to Bolt Biotherapeutics's net margin of --. Bolt Biotherapeutics's return on equity of -64.69% beat Internet Patents Corporation's return on equity of --.

Bolt Biotherapeutics has a consensus price target of $1.13, signalling upside risk potential of 204.05%. On the other hand Internet Patents Corporation has an analysts' consensus of -- which suggests that it could fall by --. Given that Bolt Biotherapeutics has higher upside potential than Internet Patents Corporation, analysts believe Bolt Biotherapeutics is more attractive than Internet Patents Corporation.

Bolt Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Internet Patents Corporation has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bolt Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Internet Patents Corporation offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics pays -- of its earnings as a dividend. Internet Patents Corporation pays out -- of its earnings as a dividend.

Bolt Biotherapeutics quarterly revenues are $1.1M, which are larger than Internet Patents Corporation quarterly revenues of --. Bolt Biotherapeutics's net income of -$15.9M is higher than Internet Patents Corporation's net income of --. Notably, Bolt Biotherapeutics's price-to-earnings ratio is -- while Internet Patents Corporation's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics is 1.44x versus -- for Internet Patents Corporation. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -1330.06% compared to Bolt Biotherapeutics's net margin of --. Bolt Biotherapeutics's return on equity of -64.69% beat Theriva Biologics's return on equity of --.

Bolt Biotherapeutics has a consensus price target of $1.13, signalling upside risk potential of 204.05%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 832.84%. Given that Theriva Biologics has higher upside potential than Bolt Biotherapeutics, analysts believe Theriva Biologics is more attractive than Bolt Biotherapeutics.

Bolt Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Bolt Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Bolt Biotherapeutics quarterly revenues are $1.1M, which are larger than Theriva Biologics quarterly revenues of --. Bolt Biotherapeutics's net income of -$15.9M is lower than Theriva Biologics's net income of -$4.4M. Notably, Bolt Biotherapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics is 1.44x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.